Tuberculosis vaccine H4IC - AJ Vaccines

Drug Profile

Tuberculosis vaccine H4IC - AJ Vaccines

Alternative Names: Adjuvanted TB subunit vaccine H4IC - AJ Vaccines/sanofi pasteur; AERAS-404; Ag85B-TB10.4-IC31; H4+IC31; H4/AERAS-404+IC31®; H4/IC31 vaccine; H4:IC31; HyVac4; HyVac4-IC31; Tuberculosis vaccine H4IC - AJ Vaccines/sanofi pasteur

Latest Information Update: 18 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Statens Serum Institut
  • Developer Aeras; AJ Vaccines; National Institute of Allergy and Infectious Diseases; Sanofi Pasteur
  • Class Adjuvants; Antituberculars; Recombinant fusion proteins; Subunit vaccines; Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 11 Jul 2018 Final efficacy data from a phase II trial in Tuberculosis released by Aeras
  • 19 Feb 2018 Interim efficacy and adverse events data from a phase II trial in Tuberculosis released by Aeras
  • 19 Feb 2018 Aeras plans two phase II trials for Tuberculosis (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top